BriaCell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Year Ending	Current	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021	Jul 31, 2020	Jul 31, 2019
Market Capitalization	12	107	101	38	-	-
Market Cap Growth	-69.96%	6.00%	163.46%	-	-	-
Enterprise Value	14	86	60	-19	0	0
PE Ratio	-	-5.27	-3.76	-2.77	-	-
PB Ratio	-5.81	-28.31	9.77	1.38	-	-
P/FCF Ratio	-1.12	-4.50	-8.08	-4.94	-	-
P/OCF Ratio	-1.12	-4.50	-8.08	-4.94	-	-
EV/EBITDA Ratio	-1.62	-3.68	-3.92	2.72	-0.10	-0.04
EV/EBIT Ratio	-1.62	-3.68	-3.91	2.72	-0.10	-0.04
EV/FCF Ratio	-1.09	-3.61	-4.79	2.45	-0.30	-0.04
Debt / Equity Ratio	-	-	-	0.00	-0.11	-0.47
Debt / EBITDA Ratio	-	-	-	0.00	-0.10	-0.07
Debt / FCF Ratio	-	-	-	0.00	-0.32	-0.08
Quick Ratio	0.14	11.81	43.64	102.88	0.01	0.14
Current Ratio	0.82	14.96	45.00	103.81	0.07	0.15
Interest Coverage	-	-	-1.32	-1.02	-135.52	-183.87
Return on Equity (ROE)	157.80%	13188.10%	-85.90%	-164.00%	187.80%	-
Return on Assets (ROA)	-37.60%	-62.70%	-67.50%	-70.10%	-832.40%	-
Return on Capital (ROIC)	591.24%	616.13%	-148.02%	-25.19%	123.43%	1383.35%
Earnings Yield	-41.78%	-18.99%	-26.61%	-36.09%	-	-
FCF Yield	-214.67%	-22.21%	-12.38%	-20.24%	-	-
Buyback Yield / Dilution	-2.99%	-0.81%	-242.82%	-533.09%	-23.16%	-35.49%
Total Shareholder Return	-2.99%	-0.81%	-242.82%	-533.09%	-23.16%	-35.49%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).